**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 62804

**Manuscript Type:** EDITORIAL

**Textbook outcomes in hepatobiliary and pancreatic surgery**

Tsilimigras DI *et al*. TO after HPB surgery

Diamantis I Tsilimigras, Timothy Michael Pawlik, Dimitrios Moris

**Diamantis I Tsilimigras, Timothy Michael Pawlik,** Department of Surgery, Ohio State University, Columbus, OH 43210, United States

**Dimitrios Moris,** Department of Surgery, Duke University Medical Center, Duke University, Durham, NC 27710, United States

**Author contributions:** Tsilimigras DI and Moris D designed the work; Tsilimigras DI conducted analysis and interpretation of working data; Pawlik TM and Moris D drafted the work, and strictly revised the important knowledge content; all authors made the final approval of this version.

**Corresponding author: Dimitrios Moris, MD, MSc, PhD, Surgeon,** Department of Surgery, Duke University Medical Center, Duke University, 2310 Erwin Road, Durham, NC 27710, United States. dimmoris@yahoo.com

**Received:** January 19, 2021

**Revised:** February 12, 2021

**Accepted:** March 29, 2021

**Published online:** April 21, 2021

**Abstract**

The concept of textbook outcome (TO) has recently gained popularity in surgical research and has been used to evaluate the quality or success of different surgical procedures, including hepatopancreatobiliary (HPB) operations. TO consists of individual outcome parameters that each reflect different domains of care including structure, process, and individual outcomes; in turn, the composite TO metric represents the optimal course after a surgical episode. TO can be used to assess patient-level outcomes, hospital performance, center designation and quality metrics. In addition to being an outcome measurement, TO may also be linked to healthcare costs. Future efforts should be directed towards establishing a universal definition of TO in HPB surgery so that surgeons and hospitals can assess and compare outcomes, identify shortcomings and improve real world patient outcomes.

**Key Words:** Textbook; Outcome; Hepatopancreatobiliary; Surgery

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Tsilimigras DI, Pawlik TM, Moris D. Textbook outcomes in hepatobiliary and pancreatic surgery. *World J Gastroenterol* 2021; 27(15): 1524-1530

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i15/1524.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i15.1524

**Core Tip:** The concept of textbook outcome (TO) has recently gained popularity in surgical research and has been used to evaluate the quality or success of different surgical procedures, including hepatopancreatobiliary (HPB) operations. TO can be used to assess patient-level outcomes, hospital performance, center designation and quality metrics. Future efforts should be directed towards establishing a universal definition of TO in HPB surgery so that surgeons and hospitals can assess and compare outcomes, identify shortcomings and improve real world patient outcomes.

**INTRODUCTION**

Traditionally, quality assessment of complex surgery has focused on analyzing and evaluating individual outcome parameters, mainly complications, length of stay (LOS), in-hospital mortality, as well as 30-, 90-d mortality and readmission[1]. More recently, there has been a shift in quality assessment from individual outcome parameters to composite outcomes, which have been considered superior to assess patient outcomes and hospital performance[2-5]. A recently introduced concept, “textbook outcome” (TO) represents the optimal course following surgery that is better aligned with patient expectations around “optimal” care[2-5]. TO uses an “all-or-none” approach in which the optimal or “textbook” outcome is not achieved unless patients achieve all of the individual parameters comprising a TO[2-5].

The concept of TO has gained popularity in surgical clinical research and has been advocated as a measure to assess quality or success of complex surgical procedures, including abdominal aortic aneurysm repair, as well as hepatopancreatic, esophageal, gastric, sarcoma, colon cancer resection and transplantation[2-10]. Specifically, TO is a composite measure that aggregates various clinically important perioperative outcomes included in the definition of an “optimal” surgical episode. Such a composite measure encompasses determinants of quality of care from different domains including structure, process, and individual outcomes[2]. Indeed, each individual outcome may capture different domains of quality (*e.g.,* perioperative mortality might be related to operative volume, failure-to-rescue may be related to structure or processes of perioperative care, while LOS or readmissions may be related to discharge planning processes in place for each institution)[5]. In turn, TO is particularly relevant in the care of complex cancers, including hepatopancreatobiliary (HPB) malignancies, which require coordination across a number of specialties and through various phases of multidisciplinary treatment to achieve the best possible outcome[3,5,11]. In addition, TO can be used as a “benchmark” to track the quality of care delivered to patients and compare hospital performance across different institutions or health systems[12-14]. In this article, we highlight the existing and emerging literature on TOs in HPB surgery.

**Assessing patient-level outcomes using TO**

Although the concept of TO was initially described in 2013 by a group of colorectal surgeons in Netherlands[2], it was used for the first time to assess outcomes of patients undergoing hepatopancreatic surgery in 2018[4]. Merath *et al*[4] first assessed TO rates after hepatopancreatic surgery among Medicare beneficiaries from 2013 to 2015[4]. TO was defined as patients who experienced no postoperative complications, no prolonged LOS (*i.e.,* ≤ 75th percentile), no 90-d readmission and no 90-d postoperative mortality[4]. The study analyzed patients with all surgical indications (*i.e.,* both benign and malignant diseases) and demonstrated that TO was achieved in 44% of individuals undergoing hepatopancreatic surgery[4]. Of note, among patients who underwent pancreatic resection, TO was achieved in 47.8% following minor pancreatic resection (*i.e.,* distal pancreatectomy or other partial pancreatectomy) and 24.7% following major pancreatic resection (*i.e.,* proximal pancreatectomy, pancreaticoduodenectomy, total pancreatectomy)[4]. Similarly, while TO was achieved in 46.8% of patients undergoing minor hepatectomy, the incidence of TO decreased to 33.3% among patients who had undergone a major liver resection[4]. These data highlighted the fact that less than one-half of patients overall experienced an optimal or “textbook” outcome after hepatopancreatic surgery; in particular, achievement of TO was markedly lower among patients undergoing major pancreatic or liver resections.

Due to the inherent limitations of administrative billing databases, several important perioperative outcomes were not captured and assessed in the initial study by Merath *et al*[4]. Rather, the use single- or multi-center institutional databases that contain more granular data to provide more clinically important information and allow for a more thorough assessment of postoperative outcomes was needed. To this end, Merath *et al*[3] published a subsequent study that assessed the incidence of TO following resection of intrahepatic cholangiocarcinoma (ICC) using a multi-institutional database that incorporated 15 major HPB centers[3]. In this study, the authors defined TO as R0 resection, no perioperative transfusion, no postoperative complications, no prolonged LOS, no 30-d readmission and no 30-d mortality[3]. Among 687 patients analyzed, TO was achieved only in 25.5% of patients undergoing curative-intent resection for ICC. Younger patient age (age < 60 years), absence of preoperative jaundice, earlier T-category disease (*i.e.,* T1a, T1b), node-negative disease, and no bile duct resection were independent predictors of TO[3]. Although 30-d mortality was less than 5%, a TO was achieved in only one-fourth of patients largely due to high rates of complications and LOS, highlighting the need for further improvements in managing patients undergoing complex HPB procedures[3].

Another study examined TO after curative-intent resection of hepatocellular carcinoma (HCC)[5]. TO was defined as R0 resection, no reoperation, no severe postoperative complications (Clavien-Dindo ≥ III), no prolonged LOS, no 90-d readmission and no 90-d mortality[5]. In analyzing 605 patients, the incidence of TO was 62.3% after curative-intent resection of HCC[5]. Patients with BCLC-0 HCC and albumin-bilirubin grade grade 1 (*i.e.,* good liver function) had higher odds of achieving a TO[5]. In addition to examining perioperative outcomes, the impact of TO on long-term outcomes was also assessed. Of note, patients who experienced a TO had a better 5-year overall survival (OS) of 69.6% compared with a 5-year OS of 56.9% among individuals who did not achieve a TO[5], which was in line with previous studies on esophageal and gastric cancer[6]. Similarly, Heidsma *et al*[15] reported an incidence of TO that was 49.3% among patients undergoing resection for pancreatic neuroendocrine tumors; the odds of TO varied based on the type of procedure performed[15]. In fact, the highest TO rates were noted among individuals undergoing distal pancreatectomy (56.7%) followed by those undergoing enucleation (52.0%) and then pancreatoduodenectomy (32.5%)[15]. TO was also an independent predictor of long-term outcomes, with 3-year disease-free survival ranging from 91.7% among patients who achieved a TO to 85.2% among patients who did not[15]. These data validated the clinical relevance of TO among cancer patients, aligning the importance of surgical quality (and outcomes) with the primary goal of achieving a potentially curative operation. As more investigators integrate TO into the field of surgical oncology, TO may evolve to incorporate other variables representing domains of multidisciplinary care delivery (*i.e.,* negative margin resection, adequate lymph node sampling, receipt of neoadjuvant/adjuvant chemotherapy) to create an oncologic composite outcome measure [*i.e.,* textbook oncologic outcome (TOO)][16,17]. Although consensus as to which individual components should define a TOO has not been reached (Table 1), the use of a TOO might be a better way to characterize patient and hospital-level outcomes among cancer patients.

**Assessing hospital performance, designations and quality metrics using TOs**

Hospital performance remains an important topic among patients and stakeholders, such as insurance and pharmaceutical companies as well as the government. To date, different designations and ranking systems are available to evaluate hospital performance. Of note, teaching hospitals have been assigned with the mission to teach the next generation of physicians, support research and provide excellent patient care[18,19]. Previous studies had demonstrated contradictory results when examining individual outcome parameters (*i.e.,* mortality, morbidity, readmissions) relative to teaching hospital status[18,19]. To this point, Mehta *et al*[12] investigated the impact of teaching status on TO among Medicare beneficiaries undergoing hepatopancreatic surgery[12]. Of note, patients undergoing surgery for pancreatic cancer at a major teaching hospital were more likely to achieve a TO *vs* patients treated at a minor teaching hospital[12]. When assessing only high volume hospitals, the odds of a TO were comparable among patients treated at major *vs* minor teaching centers, highlighting that the beneficial effect of teaching hospital status was largely mediated by procedural volume and not necessarily by teaching status itself[12].

Another study investigated a commonly used ranking system, the United States News & World Report (USNWR) Best Hospital rankings, relative to TO[13]. Although the USNWR rankings are commonly used by patients and are thought to influence patient decision-making and choice of hospital to undergo treatment, a recent study demonstrated similar odds of achieving a TO among patients undergoing complex cancer surgery (*i.e.,* lung, colorectal, esophageal, liver and pancreatic resections) at honor roll (top 20 institutions) *vs* non-honor roll hospitals[13]. These data suggested that the USNWR ranking had only a minor impact on the likelihood of achieving a TO and, thus, should not necessarily been used to choose institutions to undergo complex cancer surgery. In addition, these data suggested that composite outcomes such as TO should perhaps been taken into consideration among policymakers to establish the methodology of hospital ranking systems for complex cancer surgery.

For oncologic patients, quality of care is of particular importance as patients seek a holistic, multidisciplinary care in the battle against cancer. To date, there are only 10 dedicated cancer centers (DCCs) that provide care to cancer patients[20]. Another important designation for hospitals providing cancer care is the National Cancer Institute cancer center (NCI-CC) designation, which approximately 70 institutions in the United States hold for outstanding efforts related to prevention, diagnosis and treatment of cancer[21]. In another study by Mehta *et al*[20], the authors compared outcomes of patients undergoing hepatopancreatic surgery at DCC *vs* NCI-CC for cancer[20]. Of note, patients who underwent hepatopancreatic surgery had increased odds of achieving a TO when treated at a DCC *vs* NCI-CC (pancreatic resections: 22% higher chance of a TO; liver resection: 31% higher chance of a TO), despite the fact that DCCs more frequently cared for patients with multiple comorbidities[20]. Higher TO rates translated into reduced Medicare expenditures at DCCs, which suggested a higher value proposition of DCC *vs* NCI-CC in the treatment of patients with hepatopancreatic malignancies[20].

Several other national quality metrics have been proposed to assess quality of care provided to patients. For example, hospital magnet recognition, established by the American Nurses Credentialing Center has been used to identify institutions with a focus on improving nursing care and, in turn, quality of care delivered to patients[22]. In addition, the Leapfrog Group has set a minimum annual hospital surgical volume for certain operations–including pancreatic resection (*i.e.,* > 20 pancreatic resections)–associated with improved outcomes[23]. Another quality indicator made available by the Leapfrog group is the Leapfrog safety grade which is solely focused on patient safety[23,24]. In analyzing data from 4853 Medicare beneficiaries, Merath *et al*[14] examined all 3 quality indicators (*i.e.,* leapfrog minimum volume standards, safety grade and magnet status) relative to TO following hepatopancreatic resections[14]. Of note, patients undergoing pancreatectomy at hospitals meeting met all 3 quality metrics (*i.e.,* quality trifactor) had 28% higher odds of experiencing a TO compared with individuals undergoing pancreatectomy at non-trifactor hospitals[14]. When examining each of the quality indicators separately, magnet status and safety grade A were alone not enough to confer high TO rates. Rather, the positive effect of the quality trifactor was largely mediated by the compliance with the Leapfrog minimum volume standards that were associated with lower odds of mortality and serious complications and, in turn, greater odds of TO[14].

**Assessing trends in TOs over time**

TO has also been assessed relative to changes in practice and outcomes in HPB surgery over time. By analyzing the American College of Surgeons National Surgical Quality Improvement Program database, Beane *et al*[25] reported an increase in optimal or “textbook” outcomes after pancreatic surgery in North America[25]. There was a decrease in postoperative morbidity, mortality and LOS between 2013-2017 that resulted in an increase in the incidence of TO by 3% to 5% after pancreatic surgery on a nationwide level[25]. A number of reasons might be responsible for this improvement. First, there was a decrease in superficial and deep surgical site infections, and a decrease in the rates of shock/sepsis after pancreatic resection[25]. In addition, an increase in minimally invasive pancreatic resection was noted over time (mainly robotic resection) that may have contributed to a decrease in LOS. The broad dissemination and implementation of enhanced recovery after surgery protocols over the past 5 to 10 years likely also contributed to the observed reduction in LOS[26,27]. Furthermore, the increase in TO incidence over time may also have been done to centralization of pancreatic cancer care at specialized centers and increased access to multidisciplinary oncologic teams. In turn, the modest improvement in the incidence of TO noted over time may be a reflection of the varied distribution of pancreatic cancer cases, and not an actual improvement in the majority of centers throughout the nation[25].

Indeed, by combining two multi-institutional datasets, Tsilimigras *et al*[11] analyzed the trends in TO rates after curative-intent resection of primary liver malignancies (*i.e.,* ICC and HCC) at major HPB centers over a 12-year period[11]. Overall, 62.0% of patients achieved a TO after ICC or HCC resection at major HPB centers. In assessing the trends of TO over the years, no significant improvement was noted over the study period examined (2005-2017) (*P*trend = 0.90)[11]. When analyzing the individual components comprising TO, no specific factor demonstrated an increasing trend over time (all *P*trend > 0.05). Perhaps more surprisingly, no increasing trends in TO rates were noted among patients undergoing either major (2005 to 2009: 49%; 2014 to 2017: 48%) or minor liver resection (2005 to 2009: 71%, 2014 to 2017: 71%) over the study period (both *P*trend > 0.05)[11]. Apart from TO itself, the year of surgery was also not associated with improved long-term outcomes among patients with either ICC or HCC[11]. These data highlight the fact that despite advances in surgical techniques and perioperative care, only modest improvements in the outcomes of HCC and ICC patients occurred over the last decade. In turn, there is still a long way to optimize real world outcomes among patients with HPB malignancies.

**Financial impact of TOs**

Besides representing a quality outcome measure, TO may also have financial implications. In fact, the financial impact of TO has been investigated and data have suggested that a disproportionate amount of money is spent on patients who do not achieve a TO after hepatopancreatic surgery. For example, Merath *et al*[4] noted that among patients who achieved a TO, Medicare payments were approximately $11000 less following minor hepatopancreatic resections and $14000 less for patients undergoing major resection when compared with individuals who did not achieve a TO[4]. Similarly, Mehta *et al*[12] suggested that TO resulted in an average of $5000 less in Medicare expenditures after hepatopancreatic surgery at teaching hospitals (TO: $19191, *vs* no TO: $24165, *P* < 0.001)[12]. The association of decreased overall costs with the achievement of a TO was consistent across major and minor teaching hospitals, as well as among high and low volume institutions, highlighting that TO has financial implications irrespective of the hospital setting[12]. Collectively, the data suggest that TO might be a composite metric that reflects value—*i.e.,* high quality combined with lower costs. In turn, improving TO rates after hepatopancreatic surgery may not only optimize the quality of care provided to patients, but also decrease health care costs and lead to cost-effective and high-value care.

**Advocating for wider implementation of TO in HPB Surgery**

Advocates of TO note that this composite metric provides a more comprehensive estimate of quality of perioperative care[28]. However, a primary criticism of TO is that there is no consensus in the literature as to what should be considered an “optimal’’ outcome after a specific operation. Moreover, patient risk factors strongly influence outcomes and require comprehensive risk adjustment in order to make valid comparisons. With the thoughtful implementation of composite quality metrics in HPB surgery, surgeons and centers will hopefully gain a better understanding of the perioperative processes of care and develop insights to improve patient outcomes. Moreover, the optimization of expectation management will be facilitated, especially in high-risk patients. Improved understanding of these gaps through the use of TO can allow systems to identify patients who are high risk of failure to achieve optimal short- and long-term outcomes after surgery and redirect resources accordingly. Thus, fundamentally the concept of TO aligns with the patient best interest, which is the ideal outcome after surgery.

**CONCLUSION**

TO provides a more realistic assessment of patient-centered perioperative care and represents the optimal experience around a surgical episode. TO should be the ideal outcome that surgeons should strive to achieve for their patients. The use of TO in cancer populations is of paramount importance as a measure of both short- and long-term outcomes. TO can be used to assess performance across different institutions as well as assess quality metrics or hospital designations. Future efforts should be directed towards establishing a universal definition of TO in HPB surgery so that surgeons and hospitals can assess and compare outcomes, as well as identify shortcomings and improve real-world patient outcomes.

**REFERENCES**

1 **Dimick JB**, Staiger DO, Baser O, Birkmeyer JD. Composite measures for predicting surgical mortality in the hospital. *Health Aff (Millwood)* 2009; **28**: 1189-1198 [PMID: 19597221 DOI: 10.1377/hlthaff.28.4.1189]

2 **Kolfschoten NE**, Kievit J, Gooiker GA, van Leersum NJ, Snijders HS, Eddes EH, Tollenaar RA, Wouters MW, Marang-van de Mheen PJ. Focusing on desired outcomes of care after colon cancer resections; hospital variations in 'textbook outcome'. *Eur J Surg Oncol* 2013; **39**: 156-163 [PMID: 23102705 DOI: 10.1016/j.ejso.2012.10.007]

3 **Merath K**, Chen Q, Bagante F, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Weiss MJ, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Cloyd JM, Pawlik TM. A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. *JAMA Surg* 2019; **154**: e190571 [PMID: 31017645 DOI: 10.1001/jamasurg.2019.0571]

4 **Merath K**, Chen Q, Bagante F, Beal E, Akgul O, Dillhoff M, Cloyd JM, Pawlik TM. Textbook Outcomes Among Medicare Patients Undergoing Hepatopancreatic Surgery. *Ann Surg* 2020; **271**: 1116-1123 [PMID: 30499800 DOI: 10.1097/SLA.0000000000003105]

5 **Tsilimigras DI**, Mehta R, Merath K, Bagante F, Paredes AZ, Farooq A, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Hospital variation in Textbook Outcomes following curative-intent resection of hepatocellular carcinoma: an international multi-institutional analysis. *HPB (Oxford)* 2020; **22**: 1305-1313 [PMID: 31889626 DOI: 10.1016/j.hpb.2019.12.005]

6 **van der Kaaij RT**, de Rooij MV, van Coevorden F, Voncken FEM, Snaebjornsson P, Boot H, van Sandick JW. Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery. *Br J Surg* 2018; **105**: 561-569 [PMID: 29465746 DOI: 10.1002/bjs.10729]

7 **Karthaus EG**, Lijftogt N, Busweiler LAD, Elsman BHP, Wouters MWJM, Vahl AC, Hamming JF; Dutch Society of Vascular Surgery, the Steering Committee of the Dutch Surgical Aneurysm Audit, the Dutch Institute for Clinical Auditing. Textbook Outcome: A Composite Measure for Quality of Elective Aneurysm Surgery. *Ann Surg* 2017; **266**: 898-904 [PMID: 28746156 DOI: 10.1097/SLA.0000000000002388]

8 **Moris D**, Shaw BI, Gloria J, Kesseli SJ, Samoylova ML, Schmitz R, Manook M, McElroy LM, Patel Y, Berg CL, Knechtle SJ, Sudan DL, Barbas AS. Textbook Outcomes in Liver Transplantation. *World J Surg* 2020; **44**: 3470-3477 [PMID: 32488663 DOI: 10.1007/s00268-020-05625-9]

9 **Moris D**, Cerullo M, Nussbaum DP, Blazer DG 3rd. Textbook Outcomes Among Patients Undergoing Retroperitoneal Sarcoma Resection. *Anticancer Res* 2020; **40**: 2107-2115 [PMID: 32234903 DOI: 10.21873/anticanres.14169]

10 **Wiseman JT,** Ethun CG, Cloyd JM, Shelby R, Suarez-Kelly L, Tran T, Poultsides G, Mogal H, Clarke C, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick B, Fields R, Walle KV, Ronnekleiv-Kelly S, Howard JH, Cardona K, Grignol V. Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multi-institutional analysis of the US Sarcoma Collaborative. *J Surg Oncol.* 2020; **122**: 1189-1198 [PMID: 32696475 DOI: 10.1002/jso.26136]

11 **Tsilimigras DI**, Sahara K, Moris D, Mehta R, Paredes AZ, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Weiss M, Bauer TW, Maithel SK, Pulitano C, Shen F, Koerkamp BG, Endo I, Pawlik TM. Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. *Ann Surg Oncol* 2020; **27**: 3318-3327 [PMID: 32388742 DOI: 10.1245/s10434-020-08548-w]

12 **Mehta R**, Paredes AZ, Tsilimigras DI, Moro A, Sahara K, Farooq A, Dillhoff M, Cloyd JM, Tsung A, Ejaz A, Pawlik TM. Influence of hospital teaching status on the chance to achieve a textbook outcome after hepatopancreatic surgery for cancer among Medicare beneficiaries. *Surgery* 2020; **168**: 92-100 [PMID: 32303348 DOI: 10.1016/j.surg.2020.02.024]

13 **Mehta R**, Tsilimigras DI, Paredes AZ, Sahara K, Moro A, Farooq A, White S, Ejaz A, Tsung A, Dillhoff M, Cloyd JM, Pawlik TM. Comparing textbook outcomes among patients undergoing surgery for cancer at U. S. News & World Report ranked hospitals. *J Surg Oncol* 2020; **121**: 927-935 [PMID: 32124433 DOI: 10.1002/jso.25833]

14 **Merath K**, Mehta R, Tsilimigras DI, Farooq A, Sahara K, Paredes AZ, Wu L, Moro A, Ejaz A, Dillhoff M, Cloyd J, Tsung A, Pawlik TM. Quality of Care Among Medicare Patients Undergoing Pancreatic Surgery: Safety Grade, Magnet Recognition, and Leapfrog Minimum Volume Standards-Which Quality Benchmark Matters? *J Gastrointest Surg* 2021; **25**: 269-277 [PMID: 32040811 DOI: 10.1007/s11605-019-04504-6]

15 **Heidsma CM**, Hyer M, Tsilimigras DI, Rocha F, Abbott DE, Fields R, Smith PM, Poultsides GA, Cho C, Maithel SK, Pawlik TM; Other Members of the US Neuroendocrine Tumor Study Group. Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. *J Surg Oncol* 2020; **121**: 1201-1208 [PMID: 32185804 DOI: 10.1002/jso.25900]

16 **Nicholas E,** van Roessel S, de Burlet K, Hore T, Besselink MG, Connor S. Using Textbook Outcomes to benchmark practice in pancreatic surgery. *ANZ J Surg. 2021* **91**: 361-366[PMID: 33475226 DOI: 10.1111/ans.16555]

17 **van Roessel S,** Mackay TM, van Dieren S, van der Schelling GP, Nieuwenhuijs VB, Bosscha K, van der Harst E, van Dam RM, Liem MSL, Festen S, Stommel MWJ, Roos D, Wit F, Molenaar IQ, de Meijer VE, Kazemier G, de Hingh IHJT, van Santvoort HC, Bonsing BA, Busch OR, Groot Koerkamp B, Besselink MG; Dutch Pancreatic Cancer Group. Textbook Outcome: Nationwide Analysis of a Novel Quality Measure in Pancreatic Surgery. *Ann Surg* 2020; **271:** 155-162 [PMID: 31274651 DOI: 10.1097/SLA.0000000000003451]

18 **Shahian DM**, Nordberg P, Meyer GS, Blanchfield BB, Mort EA, Torchiana DF, Normand SL. Contemporary performance of U.S. teaching and nonteaching hospitals. *Acad Med* 2012; **87**: 701-708 [PMID: 22534588 DOI: 10.1097/ACM.0b013e318253676a]

19 **Taylor DH Jr**, Whellan DJ, Sloan FA. Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries. *N Engl J Med* 1999; **340**: 293-299 [PMID: 9920955 DOI: 10.1056/NEJM199901283400408]

20 **Mehta R**, Tsilimigras DI, Paredes AZ, Sahara K, Dillhoff M, Cloyd JM, Ejaz A, White S, Pawlik TM. Dedicated Cancer Centers are More Likely to Achieve a Textbook Outcome Following Hepatopancreatic Surgery. *Ann Surg Oncol* 2020; **27**: 1889-1897 [PMID: 32108924 DOI: 10.1245/s10434-020-08279-y]

21 **National cancer Institute.** Office of Cancer Centers.Cancer centers program. [cited 14 January 2021]. Available from: https://imaging.nci.nih.gov/nbia-search-cover/

22 **Friese CR**, Xia R, Ghaferi A, Birkmeyer JD, Banerjee M. Hospitals In 'Magnet' Program Show Better Patient Outcomes On Mortality Measures Compared To Non-'Magnet' Hospitals. *Health Aff (Millwood)* 2015; **34**: 986-992 [PMID: 26056204 DOI: 10.1377/hlthaff.2014.0793]

23 **Leapfrog Group.** Proposed changes to the 2019 leapfrog hospital survey.[cited 14 January 2021]. Available from: https://www.leapfroggroup.org/sites/default/files/Files/LeapfrogHospitalSurvey\_ProposedChanges\_2019\_Final.pdf

24 **Hota B**, Webb T, Chatrathi A, McAninch E, Lateef O. Disagreement Between Hospital Rating Systems: Measuring the Correlation of Multiple Benchmarks and Developing a Quality Composite Rank. *Am J Med Qual* 2020; **35**: 222-230 [PMID: 31253048 DOI: 10.1177/1062860619860250]

25 **Beane JD**, Borrebach JD, Zureikat AH, Kilbane EM, Thompson VM, Pitt HA. Optimal Pancreatic Surgery: Are We Making Progress in North America? *Ann Surg* 2019 [PMID: 31663969 DOI: 10.1097/SLA.0000000000003628]

26 **Morgan KA**, Lancaster WP, Walters ML, Owczarski SM, Clark CA, McSwain JR, Adams DB. Enhanced Recovery After Surgery Protocols Are Valuable in Pancreas Surgery Patients. *J Am Coll Surg* 2016; **222**: 658-664 [PMID: 26916130 DOI: 10.1016/j.jamcollsurg.2015.12.036]

27 **Agarwal V**, Thomas MJ, Joshi R, Chaudhari V, Bhandare M, Mitra A, deSouza A, Ambulkar R, Shrikhande SV. Improved Outcomes in 394 Pancreatic Cancer Resections: the Impact of Enhanced Recovery Pathway. *J Gastrointest Surg* 2018; **22**: 1732-1742 [PMID: 29777454 DOI: 10.1007/s11605-018-3809-7]

28 **Fong Y**. Textbook Outcome Nomograms as Multivariate Clinical Tools for Building Cancer Treatment Pathways and Prognosticating Outcomes. *JAMA Surg* 2019; **154**: e190572 [PMID: 31017642 DOI: 10.1001/jamasurg.2019.0572]

**Footnotes**

**Conflict-of-interest statement:** There has nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 19, 2021

**First decision:** February 10, 2021

**Article in press:** March 29, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Piardi T **S-Editor:** Fan JR **L-Editor: A P-Editor:** Ma YJ

**Table 1 Existing literature around textbook outcome in hepatopancreatobiliary surgery**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study period** | **Database** | **Indication** | **Components of TO** | **TO rates** |
| Merath *et al*[3], 2019 | 2013-2015 | Medicare | Benign and malignant hepatopancreatic lesions | No complications. No prolonged LOS. No 90-d mortality. No 90-d readmission | 44.0% |
| Merath *et al*[4], 2020 | 1993-2015 | Multi-institutional ICC database | Intrahepatic cholangiocarcinoma | R0 resection No transfusion. No complications. No prolonged LOS. No 30-d mortality. No 30-d readmission | 25.5% |
| Tsilimigras *et al*[5], 2020 | 2000-2015 | Multi-institutional HCC database | Hepatocellular carcinoma | R0 resection No reoperation. No complications (Clavien-Dindo ≥ III) No prolonged LOS. No 90-d mortality. No 90-d readmission | 62.3% |
| Heidsma *et al*[15], 2020 | 2000-2016 | US Neuroendocrine Tumor Study Group database | Pancreatic neuroendocrine tumors | R0 resection No complications (Clavien-Dindo ≥ III). No prolonged LOS. No 90-d mortality. No 90-d readmission | 49.3% |

TO: Textbook outcome; LOS: Length of stay; ICC: Intrahepatic cholangiocarcinoma; US: Ultrasonography; HCC: Hepatocellular carcinoma.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**